NIH Scientists See Therapeutic Potential Against Bacteria, Viruses
National Institutes of Health researchers have identified a naturally occurring lipid—a waxy, fatty acid—used by a disease-causing bacterium to impair the host immune response and increase the chance of infection. Inadvertently, they also may have found a potent inflammation therapy against bacterial and viral diseases.
Lipids are known to help Francisella tularensis bacteria, the cause of tularemia, to suppress host inflammation when infecting mouse and human cells. In a new study published in the Journal of Innate Immunity, researchers from NIH’s National Institute of Allergy and Infectious Diseases found a form of the lipid phosphatidylethanoloamine, or PE, present in the bacterium. The composition of PE found in F. tularensis differs from PE found in other bacteria. In cell-culture experiments, the researchers discovered that the natural and a synthetic form of PE reduced inflammation caused by both tularemia bacteria and dengue fever virus.
Tularemia is a life-threatening disease spread to humans via contact with an infected animal or through the bite of a mosquito, tick or deer fly. Although tularemia can be successfully treated with antibiotics, it is difficult to diagnose, mainly because F. tularensis bacteria can suppress the human immune response. Dengue fever, primarily spread by Aedes aegypti mosquitoes, is rarely fatal but usually leads to a high fever, severe headache and pain throughout the body. There is no specific treatment for dengue fever.
After identifying PE as the lipid that impaired the immune response, the scientists began to consider its potential therapeutic value. Because natural F. tularensis is highly infectious and therefore challenging to work with, the group developed synthetic lipids—PE2410 and PEPC2410—that would be much easier to study and produce. They then verified that both synthetic lipids also suppressed the immune response during infection of mouse and human cells in the laboratory.
Because several types of viral infections involve an unconstrained inflammatory response, the group tested natural and their synthetic PE in the laboratory against dengue fever virus-infected human cells. Both versions inhibited the immune response compared to the immune response seen in infected but untreated cells.
The group plans to continue exploring how F. tularensis impairs the immune response. They hope their findings will eventually lead to the development of a potent, broad-spectrum anti-inflammatory therapeutic.
Learn more: Natural Lipid Acts as Potent Anti-Inflammatory
The Latest on: Inflammation therapy
via Google News
The Latest on: Inflammation therapy
Study Points to New Therapeutic Targets for Tumours Associated with Chronic Inflammation
on July 12, 2018 at 6:20 am
"On the basis of our findings, we propose that decisions regarding therapy should take into consideration the inflammatory conditions and the levels of IGF-1 in biopsies of patients with inflammatory ... […]
NIH scientists identify natural lipid acting as potent anti-inflammatory therapy
on July 9, 2018 at 4:30 am
National Institutes of Health researchers have identified a naturally occurring lipid—a waxy, fatty acid—used by a disease-causing bacterium to impair the host immune response and increase the chance ... […]
Nextbiotix receives 7 million euros to develop bacterial IBD therapy
on July 6, 2018 at 9:02 am
Nextbiotix — a French microbiome company — announced that it received 7 million euros in series A funding to help its development of a bacteria-based treatment for inflammatory bowel disease. “We are ... […]
A common anti-inflammatory therapy may help reduce risk of developing Parkinson's disease
on April 23, 2018 at 8:02 am
Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia A recent study from researchers ... […]
A Common Anti-inflammatory Therapy May Help Reduce the Risk of Developing Parkinson’s Disease, Mount Sinai Researchers Report
on April 23, 2018 at 4:03 am
A recent study from researchers at the Icahn School of Medicine at Mount Sinai provides new insights into a link between inflammatory bowel disease (IBD) and Parkinson’s disease, and may have signific... […]
Thetis Pharmaceuticals Awarded $2.3 Million Fast-Track NIH Grant to Develop Immuno-Resolving Therapy for Inflammatory Bowel Disease
on November 16, 2017 at 9:35 pm
Nov. 16, 2017 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals, a biopharmaceutical company developing “immuno-resolving” therapies for treatment of inflammatory bowel disease ... Thetis’ TP-317 candidate a... […]
Anti-inflammatory therapy cuts risk of lung cancer
on August 28, 2017 at 7:58 am
In most clinical trials for cancer therapy, investigators test treatments in patients with advanced disease. But a recent cardiovascular secondary prevention study has given researchers a unique oppor... […]
Novel solid forms of the anti-inflammatory drug oxaprozin may lead to a new combined asthma therapy
on November 29, 2016 at 4:00 pm
An exploratory study by A*STAR scientists into novel solid forms of the anti-inflammatory drug oxaprozin may lead to improvements for the asthma drug, salbutamol, and help reduce inflammation of the a... […]
Oxygen Therapy Worsens Lung Inflammation
on May 4, 2005 at 2:50 pm
Newswise — Physicians have long known that too little oxygen (hypoxia) causes headaches, nausea, and eventually death. But too much oxygen (hyperoxia) can kill to, as evidenced in a new study by North... […]
via Bing News